Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | BTK | Q06187 | 12/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | CSF1R | P07333 | 3/20 | 0.48 |
| ▸ | RET | P07949 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530457 | 0.88 | BTK (0.54) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3528912 | 0.86 | BTK (0.61) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3529327 | 0.83 | BTK (0.72) | KDRBTK | |
| SCHEMBL3531001 | 0.82 | EPHB4 (0.64) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3529981 | 0.81 | BTK (0.70) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3565790 | 0.81 | BTK (0.67) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3524727 | 0.80 | KDR (0.53) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3529381 | 0.79 | BTK (0.58) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3531844 | 0.79 | KDR (0.57) | KDRAURKBAURKABTKMAP4K4 | |
| SCHEMBL3526917 | 0.78 | EPHB4 (0.56) | BTKLCKEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373662-B1 | THIENO[3,2-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | ABBVIE BAHAMAS LTD (BS) | 2014-09-24 | — | — | EP | disclosed |
| US-8722890-B2 | Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile | ABBVIE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120309783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | ABBOTT LABORATORIES (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100144783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | KDR 511/4885AURKB 262/4885AURKA 293/4885 |
| US-20100144783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | CYP3A43, CYP3A4, CYP1A2 | KDR 28/4885AURKB 14/4885AURKA 18/4885 |
| US-20120309783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | CYP3A43, CYP3A4, CYP1A2 | KDR 28/4885AURKB 14/4885AURKA 18/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885AURKA 207/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885AURKA 207/4885 |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885AURKA 207/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885AURKA 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.